Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments
Oral GLP-1, Injectable GGG Agonists Moving Into Phase III
Lilly will increase spending, resulting in lower-than-expected EPS, to drive its revenue growth, relying on sales of new products, particularly its next generation of incretin agonists for diabetes and obesity.
You may also be interested in...
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.
J.P. Morgan Day Four: Talking With Execs About BD Plans
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.